Radiation has never been more important in cancer care

Radiation has always been a critical part of cancer care, but efficacy has generally been limited in the metastatic setting, while high dosage radiation has come with unwanted side effects. The evolution from external-beam radiation to systemically-delivered and targeted radiation is transforming the use of radiation in cancer care, across the spectrum of diagnostics and staging, to surgical intervention.

Telix is developing targeted radiation therapies with the potential to be efficacious as stand-alone treatments or as complements to existing treatment modalities, addressing areas of high unmet medical need. We pair each therapeutic with a diagnostic imaging agent. This underpins the theranostic approach whereby two conjugates are used to target the same cell-surface receptor: one for detection, localisation or staging, and the other for selective destruction of target cancer cells. When used in tandem to plan and execute treatment, and then to assess response and monitor for progression, this approach allows the delivery of truly personalised therapy to patients.

Illuccix® for prostate cancer imaging

PSMA PET/CT technology is a breakthrough in prostate cancer diagnosis. Illuccix (kit for the preparation of Ga-68 Glu-urea-Lys(ahx)-hbed-CC Injection), also known as 68Ga-PSMA-11 injection), Telix’s lead prostate cancer imaging agent has received U.S. Food and Drug Administration (FDA), Australian Therapeutic Goods Administration (TGA), and Health Canada approval. Approved indications include staging of high-risk patients, identification of suspected recurrence, and selection for PSMA-directed lutetium therapy.